Please ensure Javascript is enabled for purposes of website accessibility

Bristol Myers Squibb's Multiple Sclerosis Drug, a Potential Blockbuster, Wins FDA Approval

By Keith Speights - Mar 26, 2020 at 9:29AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

But the big drugmaker will delay its commercial launch due to the COVID-19 pandemic.

Bristol Myers Squibb (BMY 1.64%) announced on Thursday that the Food and Drug Administration has approved Zeposia (ozanimod) for treating adults with relapsed multiple sclerosis (MS), an autoimmune disease where the body's immune system attacks the protective myelin sheathes that cover its nerves. The FDA approval was based on two large late-stage clinical studies in which Zeposia demonstrated higher efficacy than Biogen's MS drug Avonex.

A second effort

Celgene first filed for FDA approval of ozanimod in 2018. However, the FDA sent the biotech a Refusal to File letter stating that the application for the drug wouldn't even be considered because the submission didn't include all of the required information for a review. 

Businessman holding card that has "FDA approved" printed on it

Image source: Getty Images.

Celgene resubmitted its application in March 2019, less than three months after Bristol Myers Squibb announced its plans to acquire the biotech. That acquisition closed in November.

Blockbuster potential -- eventually

Zeposia's efficacy and convenience as a once-daily oral medication should appeal to physicians and patients. Celgene estimates that the drug could generate peak annual sales of between $4 billion and $6 billion if it also gains approval as a treatment for two other autoimmune diseases -- Crohn's disease and ulcerative colitis. Analysts forecast that Zeposia will rake in around $1.6 billion annually by 2024.

However, its path toward blockbuster status won't start immediately. Bristol Myers Squibb stated that it's delaying the launch of Zeposia due to the COVID-19 pandemic. The drugmaker said that it will monitor the situation and consult with the neurology community before deciding on the specific timing of the drug's launch. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$78.96 (1.64%) $1.27
Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$211.93 (0.26%) $0.55

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.